Haya, Lilly target metabolic disorders with $1B lncRNA pact

Sep 4, 2024 · The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between biotech pioneers and big pharma in the past week. Haya …

CouponFollow Extension

$1
OFF

Haya, Lilly Target Metabolic Disorders With $1B LncRNA Pact

4 weeks from now

Sep 4, 2024 · The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between biotech pioneers and big pharma in the past week. Haya …

bioworld.com

$1
OFF

Lilly Lays Down $1B To Be ‘first In Biology’ With Obesity Gene ...

4 weeks from now

Sep 9, 2024 · The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies. ... Lilly lays down $1B to be ‘first in biology’ with obesity gene …

pharmavoice.com

$1
OFF

Lilly, Haya Ink $1B Biobuck Obesity Pact To Search Dark Genome

4 weeks from now

Sep 4, 2024 · The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets. …

fiercebiotech.com

$1
OFF

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 5, 2024 · Until now, Haya has focused its drug discovery platform on fibrotic diseases, cardiovascular and metabolic diseases, and cancer. However, preclinical studies – including …

pharmaceutical-technology.com

$1
OFF

Lilly, Haya Ink Potential $1B Drug Discovery Deal To Target

4 weeks from now

Sep 4, 2024 · Eli Lilly is diving further into the obesity space with a potential billion-dollar deal with Haya Therapeutics. The companies announced a collaboration Wednesday to utilize the Swiss …

biospace.com

$1
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · HAYA is developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in tissues that include lungs, kidneys, liver, and the …

genengnews.com

$1
OFF

Lilly To Hunt Non-coding DNA For Obesity Drugs In $1bn Deal

4 weeks from now

6 days ago · Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA. The biotech focuses on …

pharmaphorum.com

$1
OFF

Haya, Lilly Sign $1B Pact, Week's Second Deal For LncRNAs

4 weeks from now

Sep 4, 2024 · Haya Therapeutics SA announced Sept. 4 that is has sealed a multiyear agreement with Eli Lilly and Co., to apply its lncRNA platform technology to identify targets in obesity and …

bioworld.com

$1
OFF

Lilly Taps RNA Biotech For $1 Billion Weight-loss Collaboration

4 weeks from now

Sep 4, 2024 · The Lilly-Haya deal marks the second Big Pharma collaboration in as many weeks to focus on lncRNAs. Bayer recently agreed to pay NextRNA Therapeutics up to $547 million …

acs.org

$1
OFF

BioWorld Science Sept. 5, 2024

4 weeks from now

Sep 5, 2024 · Haya, Lilly target metabolic disorders with $1B lncRNA pact The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between …

bioworld.com

FAQs about Haya, Lilly target metabolic disorders with $1B lncRNA pact Coupon?

What is Haya's lncRNA collaboration?

This collaboration will utilize HAYA’s full-stack regulatory genome platform to identify, characterize and validate multiple novel lncRNA targets for the potential development of new treatments for obesity and related metabolic disorders. ...

Will Eli Lilly and Haya Therapeutics find RNA-based drug targets for obesity?

Eli Lilly and Haya Therapeutics aim to find multiple regulatory genome derived RNA-based drug targets for obesity. Credit: eamesBot via Shutterstock. Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. ...

Could Haya's lncRNA discovery lead to the development of Genetic Medicine?

“By identifying disease-driving cell states and novel lncRNA therapeutic targets, Haya’s proprietary regulatory genome discovery platform may pave the way for the development of genetic medicine therapies that modify disease cell states, augmenting the efficacy of current obesity targeting therapies.” ...

Will Lilly pay Haya a $1 billion lncRNA investment?

Lilly has agreed to pay HAYA an undisclosed upfront payment, including an equity investment, as well as up to $1 billion in payments tied to achieving preclinical, clinical, and commercial milestones, plus royalties on product sales. Lilly is the second big-name biopharma to invest in an lncRNA collaboration in as many weeks. ...

Could Haya get $1bn from Eli Lilly?

Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal. Eli Lilly and Haya Therapeutics aim to find multiple regulatory genome derived RNA-based drug targets for obesity. Credit: eamesBot via Shutterstock. ...

What is Haya's lncRNA discovery platform?

HAYA’s proprietary regulatory genome discovery platform enables the identification of tissue-, disease- and cell-specific long non-coding RNA (lncRNA) targets and the development of RNA-targeting therapies, with potentially better efficacy and less toxicity than current treatments, to reprogram disease-driving cell states. ...